EHA Unplugged

Join EHA President  Prof  Konstanze Döhner  from  University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics.  

Listen as  Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator.  Tune in to hear  Prof. Döhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those.  

Guest: Prof Konstanze Döhner, University Hospital Ulm, Germany  
Host: Isabel Olivera Martinez, PhD

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠⁠Provide Feedback⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠⁠https://ehaedu.org/Campus⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠
Facebook: ⁠⁠https://e-h-a.link/facebook⁠⁠
LinkedIn: ⁠⁠https://www.linkedin.com/company/eha/⁠⁠
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via ⁠⁠https://eha.news/subscribe⁠⁠

In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis.

Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process.

Guest: Dr Michael Milsom
Head of the Division of Experimental Hematology at the German Cancer Research Center, (DKFZ), and group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‑STEM), Heidelberg, Germany

Host: Isabel Olivera Martinez, PhD
Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠Provide Feedback⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠https://ehaedu.org/Campus⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠
Facebook: ⁠https://e-h-a.link/facebook⁠
LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠

Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden).  

In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including  the expanding role of  BTK inhibitors (such as ibrutinib) in first-line regimens. 

He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy  have largely supplanted but not fully replaced allogeneic transplantation. 
Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges. 
  
Link to the guideline: (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) 
Link to Lund University:  
Mats Jerkeman - Lund University 
Home | Lund University  

Learn More

Interested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠.

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠Provide Feedback⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠https://ehaedu.org/Campus⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠
Facebook: ⁠https://e-h-a.link/facebook⁠
LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠

[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma.
Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission.
Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions. 
 
Host: Dr Sarah de Vlieger
Guest: Jonathan Clark
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.
Learn More
Interested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠.

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠Provide Feedback⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠https://ehaedu.org/Campus⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠
Facebook: ⁠https://e-h-a.link/facebook⁠
LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠

[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.   
Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.  
The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't." 

Host: Dr Wilson Lim
Guest: Dr Gregor Hormann

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠Provide Feedback⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠https://ehaedu.org/Campus⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠
Facebook: ⁠https://e-h-a.link/facebook⁠
LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠